Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3CNS 2Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Melanoma 3Uveal Melanoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solutions × Dermatologic × 1 year × Clear all
NCT04752826 2026-02-18

MK-3475-D20

BioInvent International AB

Phase 1/2 Recruiting
176 enrolled
DermatologicGynecologicLymphoid

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT07230613 2026-02-11

NEOREM-NEO-1

UNICANCER

Phase 2 Recruiting
50 enrolled
Dermatologic

Melanoma

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

BioInvent International AB

Phase 1/2 Active not recruiting
35 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡